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Genome-wide association studies (GWAS) have been highly successful in identifying genetic 
variation associated with type 2 diabetes (T2D) risk and related quantitative traits (1–3). The vast 
majority of association signals are located in non-coding regions of the genome, influencing nearby 
genes through regulation of transcriptional, translational, or splicing activity (4). Due to the highly 
context-dependent nature of gene expression, the effects of many risk variants are restricted to spe-
cific cell types and produce more subtle effects than those observed in organism-wide (or “global”) 
knockouts. In addition, identification of the underlying causal genes and target tissues is often a 
major challenge, hindering translation into disease mechanisms. Recent studies have shown that 
the intersection of genetic data and genomic annotations can be used to produce a cellular atlas 
with which to understand the phenotypes of GWAS signals. Through the generation of directed 
hypotheses, this integrated framework has the potential to bridge the gap between association signals 
and disease biology.
THE BASiS FOR TiSSUE SpECiFiCiTY
Across the human population, differences in complex traits, such as height and disease suscepti-
bility, are influenced by the presence of single-nucleotide polymorphisms (SNPs). Some of these 
genetic variants modulate binding of transcription factors (TFs), which in turn drive differences 
in gene expression (5, 6). TF binding is also influenced by co-factors and chromatin state, which 
are highly dependent on cell type and developmental stage. To establish and maintain cellular 
identity, cell-type-specific TFs tend to bind in clusters, often referred to as cis-regulatory modules 
(7–9). Intriguingly, association signals for T2D have been found to show a significant overlap with 
islet-selective enhancer clusters (9, 10). Although other tissues have also been implicated in T2D 
susceptibility, this is consistent with physiological studies establishing islet dysfunction as a central 
mechanism of disease-associated variants (1, 11–13).
The overlap between T2D signals and enhancer clusters suggests that the effect of risk variants 
could be subject to the same tissue specificity observed at the level of regulatory activity (11). In other 
words, a motif-altering allele would only be expected to produce a molecular phenotype in those 
contexts (cell type or developmental stage) where the binding site has the potential to be occupied. 
In support of this notion, T2D risk variants were found to be enriched for nearby binding sites of 
the pioneer TF FOXA2 in islet and liver (14). T2D-association signals also show a significant overlap 
with SNPs affecting islet expression of regional transcripts, so-called cis-expression quantitative trait 
loci (cis-eQTL), most of which are not found to be eQTLs in other tissues (15). Together, these 
general observations outline some of the context-dependent effects that T2D risk variants can be 
subject to.
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COnTEXT SpECiFiCiTY OF CAUSAL 
MECHAniSMS FOR T2D SUSCEpTiBiLiTY
Recent studies have provided more specific evidence to support 
the notion that context specificity is a key aspect of GWAS causal 
mechanisms. The following cases collectively provide examples 
of mechanisms where studying the right tissue, species, and 
developmental stage proved critical to uncovering the relevant 
phenotypes.
At the MTNR1B locus, a convergence of evidence has pointed to 
effects of a non-coding T2D-association signal on the pancreatic 
β cell. Physiological studies have revealed a phenotype indicative 
of β-cell dysfunction in risk-variant carriers, with some evidence 
for additional effects on insulin action (12, 16, 17). Fine-mapping 
efforts identified a single likely causal variant that overlaps active 
islet and liver enhancers, and a cis-eQTL for MTNR1B in islets 
(14, 15, 18, 19). The risk allele, which increases islet MTNR1B 
expression, was predicted to create a NEUROD1 binding site and 
shown to selectively bind this key TF in human β cells. These 
results establish a likely causal mechanism for the non-coding 
risk allele, and illustrate how motif-altering alleles can generate 
highly tissue-specific effects. Surprisingly, exon re-sequencing of 
the MTNR1B gene has also shown coding loss-of-function (LOF) 
mutations to be associated with increased risk of T2D (20). The 
reason for the opposite directions of effect observed for coding 
and non-coding risk variants is unclear but may reflect differ-
ences between global and islet-specific roles of MTNR1B.
In the case of PTF1A, studying the right tissue proved neces-
sary but not sufficient to elucidating the underlying mechanism 
for non-coding mutations in the region. Previous work had 
identified a group of patients suffering from unexplained isolated 
pancreatic agenesis, which includes neonatal diabetes as a clinical 
feature (21). To filter causal mutations from incidental variation, 
one study used pancreatic endoderm to define regulatory regions 
that are active during pancreatic development (22). Their strategy 
identified a distal enhancer that harbors mutations abolishing 
enhancer activity toward PTF1A (23). Coding LOF variants in 
PTF1A had previously implicated the gene in syndromic pan-
creatic agenesis, characterized by severe neurological features in 
affected individuals. The observation that the identified enhancer 
region is not active in any cell type other than pancreatic endo-
derm provides a plausible explanation for the absence of any 
cerebral defects (22). Remarkably, even adult pancreatic tissue 
did not show active chromatin marks in the region, highlighting 
that studying the right developmental stage was critical to the 
success of the approach.
The mechanisms underlying GWAS signals are sometimes 
studied using individuals that carry LOF mutations in positional 
candidate genes. The observed phenotypes will be a function of 
global effects across all the tissues where the gene is expressed, 
which may confound or mask the more context-dependent 
actions of regulatory risk alleles. At the CDKN2A locus, non-
coding T2D signals have been robustly associated with measures 
of islet dysfunction, and a number of studies have established 
effects of CDKN2A on insulin secretion and cellular senescence 
in β-cells (12, 24, 25). By contrast, coding LOF mutations in 
CDKN2A, which are a cause of familial melanoma, were recently 
shown to result in a metabolic phenotype consistent with effects 
on both liver and β-cells (26). This discrepancy was proposed 
to arise from islet-specific TF binding of the enhancer region 
containing the T2D signals.
In animal studies, context-dependent knockouts can provide 
improved spatial and temporal resolution for targeting candidate 
causal genes. Even so, the disease relevance of the observed 
phenotypes is determined by the confidence with which the 
target tissue of the risk allele is known. One example is provided 
by an intronic T2D signal at the TCF7L2 locus, which has been 
the focus of conflicting observations. Tissue-specific knockout 
studies have demonstrated primary roles of TCF7L2 in a number 
of different tissues, including liver and islets, whereas the non-
coding GWAS signal has been consistently associated with a 
relatively narrow insulin secretion defect. Genomic annotations 
provide a clue as to the underlying reason, with the risk variants 
being located in an islet-specific region of open chromatin (8, 10, 
27). Furthermore, the region has chromatin marks indicative of 
regulatory activity in islets, but not in a wide range of other tissues 
(10). The annotations can, thus, be applied as a filter to exclude 
non-disease-relevant tissues, and guide efforts to study the effect 
of the risk allele in the most appropriate context.
Coding GWAS variants can also produce context-dependent 
mechanisms through the restricted expression of gene isoforms. 
A striking example of this is provided by a coding variant 
identified in the TBC1D4 gene in a small founder population 
of Greenlandic Inuit (28). The risk allele, which produces a 
truncated transcript that results in nonsense-mediated decay, is 
positioned in an exon excluded from the short isoform of the 
transcript. Unlike the widely expressed short isoform, the long 
form is predominantly expressed in skeletal muscle (29). The 
decreased insulin sensitivity resulting from reduced expression 
of TBC1D4 is, therefore, selectively imposed on muscle tissue. As 
a result, the risk variant has a different effect on fasting glucose 
from that observed in individuals carrying LOF mutations affect-
ing both isoforms (28).
Similar to alternative spliceforms, gene homologs can con-
tribute to concealing the primary effect of a GWAS signal in a 
specific context. At the ADCY5 locus, T2D risk alleles have been 
linked to both decreased islet expression of the ADCY5 gene and 
β-cell dysfunction, though the underlying molecular mechanism 
remains unclear (12, 15). Expression studies in rodents have 
shown Adcy5 to be nearly undetectable compared with the closely 
related homolog Adcy6 (30, 31). By contrast, human islets show 
roughly equal expression of these orthologous genes, hinting at a 
non-conserved function of ADCY5 between the species (30, 32). 
It also highlights an underlying species-specificity that makes 
rodents less well suited as models for mechanistic studies.
LiMiTATiOnS OF TRADiTiOnAL 
AppROACHES
The examples above demonstrate that the molecular pheno-
types of GWAS signals can be modulated by a multitude of 
context-dependent factors. In the case of non-coding variants, 
tissue- or developmentally restricted activity of the surround-
ing chromatin can limit effects on gene expression. For coding 
FiGURE 1 | Translating GWAS signals into disease mechanisms using traditional and integrative approaches. The top panel shows a schematic 
representation of a GWAS locus with a non-coding association signal for T2D risk located near two genes, A and B. The left-hand side represents the traditional 
approach followed for elucidating the causal mechanisms leading to a T2D phenotype. This approach can produce a range of phenotypes that are difficult to 
translate into causal GWAS mechanisms, because the selected genes are often knocked out globally (bottom left panel), or in a tissue-specific context that is 
irrelevant to understanding the effects of the T2D susceptibility phenotype (bottom center panel). Sequencing approaches can also be used to identify gain-of-
function mutations (not shown), which are subject to the same limitations. The right-hand side outlines an alternative approach using integration of emerging 
datasets to produce directed hypotheses. For optimal resolution, several types of genetic and genomic datasets can be integrated, including TF binding, enhancer 
regions (defined based on chromatin state), and cis-regulatory relationships (e.g., identified by cis-eQTL or chromatin-conformation capture studies). In this example, 
the GWAS signal is observed to disrupt an enhancer cluster with cis-regulatory activity toward gene B. Importantly, the disruption exclusively affects enhancer 
activity in disease-relevant tissues. This proposes a follow-up experiment for manipulation of gene B in a specific context (bottom right panel), producing a 
phenotype that is likely to be directly relevant to understanding the molecular basis of T2D susceptibility.
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variants, alternative splicing or expression of homologs can mask 
a broader phenotype to produce context-dependent effects. These 
insights have important implications for how we design studies to 
translate genetic signals into molecular mechanisms.
Traditionally, particular genes have been selected for follow-
up studies based on a combination of known candidate-gene 
biology and proximity to the GWAS signal (Figure 1, left). For 
whole-organism gene knockouts, this could involve engineering 
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of animal models or using genetic testing to identify individu-
als carrying LOF variants. As discussed, the relevance of these 
approaches for delineating disease-relevant mechanisms is 
limited by the potential for unspecific global phenotypes. Tissue-
specific knockouts provide higher spatiotemporal resolution but 
require the target tissue(s) of the GWAS signal to be known. 
Human physiological associations can narrow down the list of 
likely relevant tissues, but these measures are often too crude to 
pinpoint specific cell types.
In principle, using animal models to target non-coding 
regions could produce more precise disease models, but this 
strategy is constrained by the low conservation at the level of 
regulatory architecture. In a study of the Cdkn2a locus in mice, 
targeted deletion of a 70  kb non-coding interval established 
enhancer activity toward nearby genes, but the relevance to 
humans has been questioned by subsequent findings (33, 34). 
The region encodes a long non-coding RNA that has no clear 
ortholog in rodents, highlighting the possibility of divergent cis-
regulatory mechanisms. More generally, TF binding sites have 
been shown to diverge even faster than the underlying sequence 
itself (35). For two key liver TFs, the majority of binding events 
were shown to be species specific, while only 10–30% of hepatic 
enhancer clusters have corresponding rodent orthologs (36, 37). 
Although subsets of conserved clusters may aid in the prioritiza-
tion of causal variants, these observations suggest that a different 
approach is required to delineate GWAS mechanisms (37, 38).
Even in those cases where animal models do provide targeted 
gene manipulation in an appropriate context (whether through 
tissue-specific knockout or transcriptional dysregulation), the 
resulting phenotypes may not be directly relevant for under-
standing human disease. Though rodent models continue to be 
an important tool for studying type 2 diabetes pathogenesis, it has 
become increasingly clear that murine pancreatic islets differ in a 
number of ways from their human counterparts (39–41). Certain 
monogenic forms of diabetes are, therefore, not well recapitulated 
in rodents, and molecular mechanisms elucidated in animal 
models should be interpreted with caution (42).
TOWARD An inTEGRATED 
UnDERSTAnDinG OF GWAS SiGnALS
To successfully study disease-relevant phenotypes, experimental 
designs can be guided by the integration of genetic association 
data and genomic annotations (Figure 1, right). At the core of this 
framework is the overlaying of a static dataset – a list of variants 
linked to disease susceptibility and/or physiological traits – with 
layers of highly dynamic functional information that provide 
spatial and temporal dimensions. These layers encompass diverse 
datasets, and include information centered on single variants, 
such as histone marks and TF binding sites, and higher-order 
information that signifies relationships between distinct ele-
ments, such as chromatin interactions and cis-eQTL data.
Genomic annotations provide a cellular atlas with which to 
navigate and interpret genetic data in the context of specific cell 
types and developmental stages. For instance, if a set of likely 
causal variants has been identified from GWAS or fine-mapping 
studies, the tissue of action may be inferred from comparing 
chromatin states across cell types (8–11, 43–46). Conversely, 
if the target tissue is known from physiological associations, 
the causal mechanism can be pinpointed by overlaying with 
relevant functional annotations (14, 22, 47–51). This process 
generates a plethora of directed hypotheses that can be fol-
lowed up with specific functional experiments. Increasingly, 
such studies are likely to be focused on differentiated cells 
derived from human stem cells, which can provide disease 
models and chromatin maps that are both functionally and 
developmentally relevant.
The broader applicability of this approach is, in part, deter-
mined by the tractability of individual loci. For regions with 
extensive linkage disequilibrium, the arising complexity can 
hinder experimental follow-up. Starting from a limited set of 
credible variants is, thus, essential. More generally, the value 
in taking an integrative approach is dictated by the extent to 
which genomic annotations for disease-relevant tissues have 
been made available (or can be obtained). The construction 
of a truly integrated framework is an incremental and monu-
mental effort, facilitated by the Encyclopedia of DNA Elements 
(ENCODE) and the NIH Roadmap Epigenomics project, which 
together cover hundreds of tissues and epigenetic annotations. 
Since each dataset is merely a snapshot of a given cell type in 
a particular metabolic and developmental state, this on-going 
process will continue to produce an atlas with ever-finer spa-
tiotemporal resolution. For many hard-to-obtain organs, such 
as pancreatic islets, power to detect relevant genomic features 
is still limiting.
Even so, chromatin landscapes for tissues relevant to T2D have 
begun to emerge in recent years, enabling biological inferences 
to be made. As we have seen, this has successfully uncovered 
tissue- and species-specific effects of T2D risk variants. The 
insights have also provided compelling evidence to demonstrate 
that context-dependent phenotypes are not the exception but, in 
fact, a fundamental aspect of GWAS biology. In the coming years, 
we need to build on this paradigm to accelerate the translation of 
genetic findings into molecular mechanisms.
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